High-quality structural information is no longer a nice-to-have in modern drug discovery and biologics development — it's a prerequisite. From early target validation through lead optimization and mechanism-of-action studies, the structural biology method you choose has a direct impact on timelines, risk, and decision quality. Yet selecting the right approach is rarely straightforward.
X-ray crystallography, Cryo-Electron Microscopy (Cryo-EM), and Cryo-Electron Tomography (Cryo-ET) each play a critical role in today's discovery workflows. They differ not only in resolution, but in the type of biological question they can answer, whether studies are performed on purified samples or in native context, how well they handle heterogeneity and dynamics, and their speed, scalability, and suitability for iterative design.
Increasingly, successful programs rely on more than one technique — combining methods to build confidence, reduce uncertainty, and move faster through key milestones.
Structural insights are most valuable when they provide a clear path forward for a program. They help teams accelerate hit-to-lead and lead optimization, understand binding modes and selectivity drivers, support biological characterization and MoA hypotheses, and generate robust evidence for downstream development and manufacturing.
In this context, choosing a structural biology method is not just a technical decision, it's a strategic program choice. It defines what evidence you can generate, how quickly you can iterate, and which risks you can retire at each stage.
Our whitepaper, "X-Ray, Cryo-EM, or Cryo-ET? A Decision Framework," provides a practical comparison of these three core techniques — outlining when and why to use each method, how they complement one another, and how an integrated, multi-modal strategy can de-risk complex discovery projects.
